These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28230352)

  • 1. Disease-Modifying Effects of M
    Lebois EP; Schroeder JP; Esparza TJ; Bridges TM; Lindsley CW; Conn PJ; Brody DL; Daniels JS; Levey AI
    ACS Chem Neurosci; 2017 Jun; 8(6):1177-1187. PubMed ID: 28230352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hippocampal place cell dysfunction and the effects of muscarinic M
    Galloway CR; Ravipati K; Singh S; Lebois EP; Cohen RM; Levey AI; Manns JR
    Hippocampus; 2018 Aug; 28(8):568-585. PubMed ID: 29742799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
    Fisher A; Pittel Z; Haring R; Bar-Ner N; Kliger-Spatz M; Natan N; Egozi I; Sonego H; Marcovitch I; Brandeis R
    J Mol Neurosci; 2003; 20(3):349-56. PubMed ID: 14501019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s Disease.
    Fisher A; Bezprozvanny I; Wu L; Ryskamp DA; Bar-Ner N; Natan N; Brandeis R; Elkon H; Nahum V; Gershonov E; LaFerla FM; Medeiros R
    Neurodegener Dis; 2016; 16(1-2):95-110. PubMed ID: 26606130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Selective M
    Lebois EP; Trimper JB; Hu C; Levey AI; Manns JR
    ACS Chem Neurosci; 2016 Oct; 7(10):1393-1405. PubMed ID: 27479319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease.
    Wu X; Kosaraju J; Zhou W; Tam KY
    ACS Chem Neurosci; 2017 Mar; 8(3):676-685. PubMed ID: 28032988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.
    Digby GJ; Noetzel MJ; Bubser M; Utley TJ; Walker AG; Byun NE; Lebois EP; Xiang Z; Sheffler DJ; Cho HP; Davis AA; Nemirovsky NE; Mennenga SE; Camp BW; Bimonte-Nelson HA; Bode J; Italiano K; Morrison R; Daniels JS; Niswender CM; Olive MF; Lindsley CW; Jones CK; Conn PJ
    J Neurosci; 2012 Jun; 32(25):8532-44. PubMed ID: 22723693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
    Fisher A
    Neurodegener Dis; 2008; 5(3-4):237-40. PubMed ID: 18322400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
    Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update.
    Fisher A
    Curr Alzheimer Res; 2007 Dec; 4(5):577-80. PubMed ID: 18220527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of selective activation of M1 and M4 muscarinic receptors on object recognition memory performance in rats.
    Galloway CR; Lebois EP; Shagarabi SL; Hernandez NA; Manns JR
    Pharmacology; 2014; 93(1-2):57-64. PubMed ID: 24480931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model.
    Li Z; Jia K; Duan Y; Wang D; Zhou Z; Dong S
    Mol Med Rep; 2017 Nov; 16(5):7835-7840. PubMed ID: 28944835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
    Chandra JN; Malviya M; Sadashiva CT; Subhash MN; Rangappa KS
    Neurochem Int; 2008 Feb; 52(3):376-83. PubMed ID: 17719699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
    Scarpa M; Hesse S; Bradley SJ
    Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons.
    Chiba T; Yamada M; Sasabe J; Terashita K; Shimoda M; Matsuoka M; Aiso S
    Mol Psychiatry; 2009 Feb; 14(2):206-22. PubMed ID: 18813209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic treatments with a 5-HT
    Baranger K; Giannoni P; Girard SD; Girot S; Gaven F; Stephan D; Migliorati M; Khrestchatisky M; Bockaert J; Marchetti-Gauthier E; Rivera S; Claeysen S; Roman FS
    Neuropharmacology; 2017 Nov; 126():128-141. PubMed ID: 28844596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study.
    Welt T; Kulic L; Hoey SE; McAfoose J; Späni C; Chadha AS; Fisher A; Nitsch RM
    J Alzheimers Dis; 2015; 46(4):971-82. PubMed ID: 25881909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using
    Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.
    Ardestani PM; Evans AK; Yi B; Nguyen T; Coutellier L; Shamloo M
    Neuropharmacology; 2017 Apr; 116():371-386. PubMed ID: 28089846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of β-amyloid in APP/tau/PS1 mouse model of Alzheimer's disease.
    Huang M; Jiang X; Liang Y; Liu Q; Chen S; Guo Y
    Exp Gerontol; 2017 May; 91():25-33. PubMed ID: 28223223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.